Kyndryl Holdings Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Kyndryl Holdings Inc trades at $12.94 (market cap $2.91B), while State Street SPDR S&P Biotech ETF trades at $159.18. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| KD | XBI | |
|---|---|---|
Market Cap | $2.91B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $33.14 | $164.28 |
52-Week Low | $10.59 | $86.92 |
Enterprise Value | $5.74B | — |
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $12.87, down 5.58% on the day, with a neutral technical signal and mixed earnings history. The company reported a net income of $252 million in 2025, reversing prior losses, and maintains strong operating cash flow of $942 million. Recent news includes an acquisition to boost AI services and Q1 2027 results showing a revenue miss but an EBITDA beat.
The stock presents a cautious opportunity with a consensus price target of $13.50, offering modest upside. Risks include inconsistent earnings, high debt levels, and ongoing investigations. Analyst sentiment is predominantly hold, reflecting uncertainty amid strategic shifts toward growth areas like AI and cloud partnerships.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Trailing returns across standard periods
Latest headlines on both assets
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →